Kalorama: EMR market tops $23B

Laura Pedulli | | Health Exec | EMR/EHR

Government incentives and the increasing use of EMRs for quality of care and cost-saving reasons helped drive the EMR market to $23.2 billion in 2013, according to a recent report published by the medical market research firm Kalorama Information.

EMR upgrading and new purchases both were factors in the growth, according to the report, “EMR 2014: The Market for EMRs,” which was the product of interviews with industry officials, consultants, healthcare providers and government personnel.

The forecast assumes the trend of adoption will continue to move forward, although slowing somewhat; hospital EMR adoption will supersede doctors EMR adoption; and current EMR Stage 3 will move up in stages, according to Kalorama.

“We think adoption and upgrading activities will still be stimulating growth in 2014-2018,” said Mary Ann Crandall, Kalorama analyst and the author of the report. “As new systems are sold, companies will still earn revenues from existing clients in servicing and consulting services."

This is the seventh year that Kalorama has studied the market for EMRs. In its total, Kalorama includes revenues for EMR/EHR systems, CPOE systems and directly related services such as installation, training, servicing and consulting. It does not include PACS or hardware.

“We estimate a quarter to a third of customers would like to switch EMRs and may look into replacing their current vendor,” said Mary Ann Crandall. “The main reasons for dissatisfaction with the system they have includes lack of key features, a cumbersome and complex interface, poor EHR usability and bad hardware. “

More on the report can be accessed here. 

 

Laura Pedulli

Related Content

Christmas ransomware exposed over 300K patient records to dark web
Private equity-backed cardiology group puts cloud-based technology in hands of its cardiologists
AI helps cardiologists deliver personalized healthcare—but there is still plenty of work to do
Indiana hospitals reduce nuisance alerts by 77% with medication decision support software
Leveraging machine learning to rapidly create clinical AI algorithms
How medication reconciliation data consolidation in the EHR enables better patient care

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.